- Home
- MRAM vs AARD Comparison
MRAM vs AARD Comparison
Compare MRAM & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRAM
- AARD
- Stock Information
- Founded
- MRAM 2008
- AARD 2017
- Country
- MRAM United States
- AARD United States
- Employees
- MRAM N/A
- AARD N/A
- Industry
- MRAM Semiconductors
- AARD Biotechnology: Pharmaceutical Preparations
- Sector
- MRAM Technology
- AARD Health Care
- Exchange
- MRAM Nasdaq
- AARD Nasdaq
- Market Cap
- MRAM 150.5M
- AARD 154.9M
- IPO Year
- MRAM 2016
- AARD 2025
- Fundamental
- Price
- MRAM $6.14
- AARD $12.73
- Analyst Decision
- MRAM Strong Buy
- AARD Strong Buy
- Analyst Count
- MRAM 1
- AARD 5
- Target Price
- MRAM $8.00
- AARD $33.00
- AVG Volume (30 Days)
- MRAM 85.1K
- AARD 39.4K
- Earning Date
- MRAM 08-06-2025
- AARD 08-14-2025
- Dividend Yield
- MRAM N/A
- AARD N/A
- EPS Growth
- MRAM N/A
- AARD N/A
- EPS
- MRAM N/A
- AARD N/A
- Revenue
- MRAM $49,110,000.00
- AARD N/A
- Revenue This Year
- MRAM $9.48
- AARD N/A
- Revenue Next Year
- MRAM $12.85
- AARD N/A
- P/E Ratio
- MRAM N/A
- AARD N/A
- Revenue Growth
- MRAM N/A
- AARD N/A
- 52 Week Low
- MRAM $4.34
- AARD $4.88
- 52 Week High
- MRAM $7.08
- AARD $19.58
- Technical
- Relative Strength Index (RSI)
- MRAM 38.89
- AARD N/A
- Support Level
- MRAM $5.88
- AARD N/A
- Resistance Level
- MRAM $6.57
- AARD N/A
- Average True Range (ATR)
- MRAM 0.23
- AARD 0.00
- MACD
- MRAM -0.11
- AARD 0.00
- Stochastic Oscillator
- MRAM 15.83
- AARD 0.00
About MRAM Everspin Technologies Inc.
Everspin Technologies Inc is a provider of Magnetoresistive Random Access Memory (MRAM) products. Its portfolio of MRAM technologies, including Toggle MRAM and Spin-transfer Torque MRAM (STT-MRAM), delivers superior performance, persistence, and reliability in non-volatile memories that transform how mission-critical data is protected against power loss. The company derives revenue from the sale of MRAM-based products in discrete unit form, licenses of and royalties on MRAM and magnetic sensor technology, the sale of backend foundry services, and design services to third parties. It recognizes revenue in three primary geographic regions; North America; Europe, the Middle East, and Africa (EMEA) and Asia-Pacific (APAC).
About AARD Aardvark Therapeutics Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.